EU RESERVES 400 MILLION DOSES OF POTENTIAL J&J COVID-19 VIRUS
The European Union said Thursday it had reserved up to 400 million doses of a potential new coronavirus vaccine developed by US giant Johnson & Johnson.
In a statement, the European Union said preliminary talks concluded on Friday for the first purchase of 200 million doses, followed by an equal number later.
The bloc said it was in “intensive discussions” with other manufacturers for potential vaccines.
According to the World Health Organization, nearly 3.7 million cases of COVID-19 have been recorded in Europe since the start of the pandemic, and 218,383 deaths.
On July 31, the European Commission said it had reserved 300 million doses of another potential vaccine being developed by French firm Sanofi.